NMRA
HealthcareNeumora Therapeutics, Inc.
$1.64
$-0.02 (-1.51%)
Jan 5, 2026
Price History (1Y)
Analysis
Neumora Therapeutics, Inc. is a biotechnology company in the healthcare sector with 95 employees and a market capitalization of $277.85M. The company's financial health is strained, with net income and EBITDA both negative at $-236,296,992 and $-240,242,000 respectively, resulting in gross margin, operating margin, and profit margin all being 0.0%. The returns on equity and assets are also negative at -104.3% and -56.7%, respectively. However, the balance sheet shows a relatively healthy cash position of $171.52M against debt of $20.09M. The company's valuation context is characterized by a forward P/E ratio of -1.57, an EV/EBITDA of -0.52, and a price to book ratio of 2.00. The beta is 3.26, indicating a relatively high level of volatility compared to the market as a whole.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $277.85M
- P/E Ratio
- N/A
- 52-Week High
- $3.25
- 52-Week Low
- $0.61
- Avg Volume
- 1.75M
- Beta
- 3.26
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 95